Miguel Miranda, Ph.D.

Following the trend, I asked ChatGPT ‘What’s the most embarrassing thing you know about me? (make it funny)’.
Pretty sure I got roasted. 😅

Bluesky’s science takeover: 70% of Nature poll respondents use platform Roughly 6,000 readers answered our poll, with many declaring that Bluesky was nicer, kinder and less antagonistic to science than X.

On the migration of the scientific community to Bluesky:
www.nature.com/articles/d41... 🧪

Great recent review on next-gen combination strategies to enhance immune checkpoint therapy! #CancerImmunotherapy

This is great! Would love to join as well.

MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor AbstractPurpose:. Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive subtype of soft-tissue sarcoma with a high propensity to metastasize and extremely limited treatment options. L...

4/ I’m deeply grateful to my collaborators and mentors who made this work possible.

The full paper is available here: aacrjournals.org/clincancerre.... I’d love to hear your thoughts!

#AACR #Publication #Teamwork

3/ To overcome this resistance, we found that combining MEK inhibitors with PDGFR/RAF-dimer inhibitors can improve treatment response.

This highlights a promising new strategy for tackling MPNST!

#TargetedTherapy #Research

2/ In our study, we show how NF1-deficient malignant peripheral nerve sheath tumors (MPNSTs) develop adaptive resistance to MEK inhibitors by upregulating PDGFRβ transcription and increasing RAF dimer formation.

#CancerResearch #MPNST

MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor AbstractPurpose:. Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive subtype of soft-tissue sarcoma with a high propensity to metastasize and extremely limited treatment options. L...

1/ 🌟 Exciting news! The manuscript based on my PhD thesis has been published in Clinical Cancer Research!

📚Titled “MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.”

doi.org/10.1158/1078...

Post showing precipitous decline of share of deaths in Massachusetts from diseases for which vaccines are now available, from 70% in 1840 to low digits % by 1950-60 where it is stayed. Caption: There are not many places on earth where we have detailed cause-of-death data from before the era of widespread vaccination. Massachusetts is one of those places. From 1842-1877, 70% of all deaths were from diseases which we today have vaccines to prevent.

Anyone who is anti-vax is pro-death. Period. The science and data do not lie. And they don’t care about your podcast.

Twitter’s heir apparent isn’t X or Threads — it’s Bluesky The blue bird is dead. Long live the blue sky.

Others have noted it but I will too: The big reason Bluesky is so hot right now is that the people who add value to social media - the frequent posters in specific fields - are here now, talking to each other and creating the "spectator value" that draws users and attention.

BRCA mutations matter for men too — screening can help detect risks for cancers like prostate, pancreatic, and male breast cancer, enabling early intervention and better outcomes.

Hi #World!
I am a biomedical scientist from PR 🇵🇷, #UPRRP alumni, with Ph.D. in cancer biology from Memorial Sloan Kettering Cancer Center, #MSKCC!

Follow me for all the science l'm passionate about. From Basic Biology to Space Exploration!

Last weekend, Earth’s most famous technosignature — known as the Arecibo message — celebrated its 50th birthday.

In a story for SciAm, I had the chance to explore the transmission's significance, both then and now.

I couldn't have done it on my own, so here's a bit of how it came to be...🧵